Several drugmakers have important clinical trial updates on the way.
Compare QURE Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: uniQure
A clinical hold is weighing on the biotech's shares today.
Agreement licenses the rights for a promising hemophilia B gene therapy.
Here are the biotechs most likely to receive juicy buyout offers in 2020.
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
Investor optimism is surging following recent M&A in gene therapy.
Steady progress with experimental gene therapies gave investors reasons to cheer.
Good news has a way of attracting suitors.
Roche's big step into the gene-editing space will spark interest for these two stocks.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.